Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant PDCD1 (Nivolumab Biosimilar) anticorps

Reactivité: Humain FACS, in vivo Hôte: Souris Monoclonal 5C4-B8 unconjugated Recombinant Antibody
N° du produit ABIN7200667
  • Antigène Tous les produits PDCD1 (Nivolumab Biosimilar)
    PDCD1 (Nivolumab Biosimilar)
    Type d'anticorp
    Recombinant Antibody
    Reactivité
    Humain
    Hôte
    • 1
    Souris
    Clonalité
    • 1
    Monoclonal
    Conjugué
    • 1
    Cet anticorp PDCD1 (Nivolumab Biosimilar) est non-conjugé
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Fonction
    Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody
    Specificité
    The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.
    Attributs du produit
    Recombinant Humanized IgG4 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Pureté
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Stérilité
    0.2 μm filtered
    niveau d'endotoxine
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogène
    The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.
    Clone
    5C4-B8
    Isotype
    IgG4 kappa
  • Indications d'application
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Agent conservateur
    Without preservative
    Conseil sur la manipulation
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Stock
    -20 °C
    Stockage commentaire
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Date de péremption
    12 months
  • Antigène
    PDCD1 (Nivolumab Biosimilar)
    Abstract
    PDCD1 (Nivolumab Biosimilar) Produits
    Synonymes
    anticorps CD279, anticorps PD-1, anticorps PD1, anticorps SLEB2, anticorps hPD-1, anticorps hPD-l, anticorps programmed cell death 1, anticorps PDCD1
    Classe de substances
    Biosimilar
    Sujet
    What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab.

    PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).

    Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity.

    The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.
Vous êtes ici:
Support technique